Cholangiocarcinoma (CCA)- Market Insights, Epidemiology and Market Forecast - 2028

Cholangiocarcinoma (CCA)- Market Insights, Epidemiology and Market Forecast - 2028

  • Pages: 210
  • Geography: Global
  • Delivery Timeline: 7-10 Business days
  • Publication: Feb, 2019
  • SKU: DIMI0501
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Glabal License
    ()
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Cholangiocarcinoma (CCA)- Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cholangiocarcinoma (CCA) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cholangiocarcinoma (CCA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028
Cholangiocarcinoma (CCA) - Disease Understanding
Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The major function of the bile duct is to move a fluid called bile from the liver and gall-bladder to the small intestine, where it helps digest the fats in food. The cause of the abnormal proliferation in the bile ducts’ epithelial cells leading to tumors are unknown and most cases occur sporadically. The malignant tumor may arises from any portion of the bile duct epithelium, i.e., anywhere from the terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural). Jaundice and abdominal pain are the most common presentations. The tumor commonly metastasizes via lymphatic spread to the regional lymph nodes, followed by hematogenous metastasis to the liver, lungs and peritoneum. Patients usually develop distant metastasis in the late stages of the disease.
It accounts for about 3% of all gastrointestinal tumours and is the second most common primary liver tumour after hepatocellular carcinoma. The majority of cholangiocarcinomas are adenocarcinomas with variable grades of differentiation (mainly well-differentiated adenocarcinomas), although several uncommon types are also encountered, such as adenosquamous, squamous, mucinous, and anaplastic carcinomas. Local and metastatic tumor growth characteristics, not histology, govern surgical resectability.

Cholangiocarcinoma (CCA) Epidemiology
The Cholangiocarcinoma (CCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Cholangiocarcinoma (CCA) are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Cholangiocarcinoma (CCA) Epidemiology Segmentation
The disease epidemiology covered in the report is segmented by incident population, type-specific incident population of Cholangiocarcinoma, gender-specific incident population, stage-specific incident population, biomarker specific and age-specific incident population of Cholangiocarcinoma.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the incident population of Cholangiocarcinoma (CCA) was estimated to be 18,729 [7MM] in 2018. United States accounts for the highest CCA cases (6,971 in 2018), followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest incident patient population of Cholangiocarcinoma, followed by Italy.
Cholangiocarcinoma (CCA) Management
The current market size for early stage Cholangiocarcinoma (CCA) majorly includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.
The primary unmet need of Cholangiocarcinoma (CCA) treatment market is the dearth of approved targeted therapies. To meet the increasing demand for the treatment of Cholangiocarcinoma (CCA), companies have shifted their focus towards the development of targeted therapies. Due to the novel and target-specific mechanism of action for Cholangiocarcinoma (CCA), the overall market size of off-label therapies will experience modest rise in the US to till 2020.
Cholangiocarcinoma (CCA) Market Outlook
The Cholangiocarcinoma (CCA) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Cholangiocarcinoma (CCA) was estimated to be USD 385.07 million in 2018. The United States accounts for the largest market size of Cholangiocarcinoma, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Currently, includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.
To meet the increasing demand for the treatment of Cholangiocarcinoma (CCA), companies have shifted their focus towards the development of targeted therapies. Expected launch of potential targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma, may increase the market size in the coming years, assisted by an increase in the incident population of Cholangiocarcinoma (CCA) & awareness of the disease.
Cholangiocarcinoma (CCA) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Cholangiocarcinoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Key players are working robustly on new therapies with novel mechanism of action, including Ivosidenib (Agios Pharmaceuticals), Pemigatinib (Incyte Corporation),   Infigratinib (QED Therapeutics), Melphalan Hydrochloride (Delcath Systems), Regorafenib (Bayer), Larotrectinib (Loxo Oncology), Entrectinib (Hoffmann-La Roche), Derazantinib (Basilea Pharmaceutica) and Erdafitinib(Janssen Research & Development).
Cholangiocarcinoma (CCA) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Cholangiocarcinoma (CCA) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition


Cholangiocarcinoma (CCA) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Cholangiocarcinoma (CCA) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Cholangiocarcinoma (CCA) market.
  • To understand the future market competition in the Cholangiocarcinoma (CCA) market.

1 Key Insights
2 Cholangiocarcinoma (CCA): Market Overview at a Glance
2.1 Total Market Share (%) Distribution of Cholangiocarcinoma (CCA) in 2017
2.2 Total Market Share (%) Distribution of Cholangiocarcinoma (CCA) in 2028
3 Cholangiocarcinoma (CCA): Disease Background and Overview
3.1 Introduction
3.2 Classification
3.3 Staging
3.3.1 Intrahepatic CCA (iCCA)
3.3.2 Perihilar CCA
3.3.3 Distal extrahepatic
3.4 Symptoms
3.5 Etiology
3.6 Pathogenesis
3.7 Biomarkers
3.8 Diagnosis
3.8.1 Differential diagnosis
3.8.2 Diagnosis of Intrahepatic CCA
3.8.3 Perihilar and distal CCA
3.8.4 Diagnostic Recommendations - British Society of Gastroenterology guidelines
3.8.5 Guidelines for the diagnosis of intrahepatic cholangiocarcinoma
4 Epidemiology and Patient Population
4.1 Key Findings
5 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in 7MM
6 United States Epidemiology
6.1 Assumptions and Rationale
6.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the United States
6.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United States
6.4 Gender Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United States
6.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in the United States
6.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in the United States
6.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United States
6.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United States
7 EU5 Epidemiology
7.1 Germany Epidemiology
7.1.1 Assumptions and Rationale
7.1.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany
7.1.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in Germany
7.1.4 Gender Specific Incident Cases of Cholangiocarcinoma in Germany
7.1.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in Germany
7.1.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in Germany
7.1.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in Germany
7.1.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in Germany
7.2 France Epidemiology
7.2.1 Assumptions and rationale
7.2.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France
7.2.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in the France
7.2.4 Gender Specific Incident Cases of Cholangiocarcinoma in France
7.2.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in France
7.2.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in France
7.2.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in France
7.2.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in France
7.3 Italy Epidemiology
7.3.1 Assumptions and Rationale
7.3.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy
7.3.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in Italy
7.3.4 Gender Specific Incident Cases of Cholangiocarcinoma in Italy
7.3.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in Italy
7.3.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in Italy
7.3.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in Italy
7.3.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in Italy
7.4 Spain Epidemiology
7.4.1 Assumptions and Rationale
7.4.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain
7.4.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in Spain
7.4.4 Gender Specific Incident Cases of Cholangiocarcinoma in Spain
7.4.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in Spain
7.4.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in Spain
7.4.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in Spain
7.4.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in Spain
7.5 United Kingdom Epidemiology
7.5.1 Assumptions and Rationale
7.5.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the United Kingdom
7.5.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United Kingdom
7.5.4 Gender Specific Incident Cases of Cholangiocarcinoma in the United Kingdom
7.5.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in the UK
7.5.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in the UK
7.5.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United Kingdom
7.5.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in the United Kingdom
8 Japan Epidemiology
8.1 Assumptions and Rationale
8.2 Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan
8.3 Type– Specific Diagnosed Incident Cases of Cholangiocarcinoma in Japan
8.4 Gender Specific Incident Cases of Cholangiocarcinoma in Japan
8.5 Stage Specific Diagnosed Incident Cases of Intrahepatic Cholangiocarcinoma in Japan
8.6 Stage Specific Diagnosed Incident Cases of Extrahepatic Cholangiocarcinoma in Japan
8.7 Biomarker Specific Diagnosed Incident Cases of Cholangiocarcinoma in Japan
8.8 Age Specific Diagnosed Incident Cases of Cholangiocarcinoma in Japan
9 Therapies and Treatment strategies
9.1.1 Treatment Recommendations – British Society of Gastroenterology guidelines
9.1.2 Guidelines for the Treatment of intrahepatic cholangiocarcinoma
9.2 Treatment Algorithm
10 Unmet Needs
11 Emerging Therapies
11.1 Key Cross Competition
11.2 Ivosidenib: Agios Pharmaceuticals
11.2.1 Product Description
11.2.2 Other Developmental Activities
11.2.3 Clinical Development
11.2.4 Safety and Efficacy
11.2.5 Product Profile
11.3 Pemigatinib: Incyte Corporation
11.3.1 Drug Description
11.3.2 Other Developmental Activities
11.3.3 Clinical Development
11.3.4 Safety and Efficacy
11.3.5 Product Profile
11.4 Infigratinib: QED Therapeutics
11.4.1 Drug Description
11.4.2 Other Developmental Activities
11.4.3 Clinical Development
11.4.4 Safety and Efficacy
11.4.5 Product Profile
11.5 Melphalan: Delcath Systems
11.5.1 Drug Description
11.5.2 Other Developmental Activities
11.5.3 Clinical Development
11.5.4 Safety and Efficacy
11.5.5 Product Profile
11.6 Derazantinib: Basilea Pharmaceutica
11.6.1 Drug Description
11.6.2 Other Developmental Activities
11.6.3 Clinical Development
11.6.4 Safety and Efficacy
11.6.5 Product Profile
11.7 Regorafenib: Bayer
11.7.1 Drug Description
11.7.2 Clinical Development
11.7.3 Safety and Efficacy
11.7.4 Product Profile
11.8 Larotrectinib: Loxo Oncology/ Bayer
11.8.1 Drug Description
11.8.2 Other Developmental Activities
11.8.3 Clinical Development
11.8.4 Safety and Efficacy
11.8.5 Product Profile
11.9 Entrectinib: Roche
11.9.1 Product Description
11.9.2 Other Developmental Activities
11.9.3 Clinical Development
11.9.4 Safety and Efficacy
11.9.5 Product Profile
11.1 Erdafitinib: Janssen Pharmaceutical
11.10.1 Product Description
11.10.2 Other Developmental Activities
11.10.3 Clinical Development
11.10.4 Safety and Efficacy
11.10.5 Product Profile
12 Cholangiocarcinoma (CCA): 7MM Market Analysis
12.1 Key Findings
12.1 Market Size of Cholangiocarcinoma (CCA) in 7MM
13 United States: Market Outlook
13.1 United States Market Size
13.1.1 Total Market size of Cholangiocarcinoma (CCA)
13.1.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in the US
14 EU-5 countries: Market Outlook
14.1 Germany Market Size
14.1.1 Total Market size of Cholangiocarcinoma (CCA)
14.1.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in Germany
14.2 France Market Size
14.2.1 Total Market size of Cholangiocarcinoma (CCA)
14.2.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in France
14.3 Italy Market Size
14.3.1 Total Market size of Cholangiocarcinoma (CCA)
14.3.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in Italy
14.4 Spain Market Size
14.4.1 Total Market size of Cholangiocarcinoma (CCA)
14.4.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in Spain
14.5 United Kingdom Market Size
14.5.1 Total Market size of Cholangiocarcinoma (CCA)
14.5.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in the UK
15 Japan Market Outlook
15.1 Japan Market Size
15.1.1 Total Market size of Cholangiocarcinoma (CCA)
15.1.2 Market Size of Cholangiocarcinoma (CCA) by Therapies in Japan
16 Market Drivers
17 Market Barriers
18 Appendix
18.1 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7:  Components of the tumor microenvironment in Cholangiocarcinoma (CCA)
Figure 8:  Factors secreted by cancer-associated fibroblasts
Figure 9:  Intracellular pathways involved in CCA proliferation and apoptosis
Figure 10:  Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 11:  Algorithm for management and diagnosis of perihilar cholangiocarcinoma.
Figure 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Figure 13: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 15: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Figure 14: Gender Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 16: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Figure 17: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Figure 18: Biomarker Specific Diagnosed Incident Cases of ICCA in the US (2017-2028)
Figure 19: Biomarker Specific Diagnosed Incident Cases of ECCA in the US (2017-2028)
Figure 20: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Figure 21: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 23: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Figure 22: Gender Specific Incident Cases of CCA in Germany (2017-2028)
Figure 24: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Figure 25: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany  (2017-2028)
Figure 26: Biomarker Specific Diagnosed Incident Cases of ICCA in Germany (2017-2028)
Figure 27: Biomarker Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 28: Age Specific Diagnosed Incident Cases of ECCA in Germany (2017-2028)
Figure 29: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 31: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Figure 30: Gender Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Figure 32: Stage Specific Diagnosed Incident Cases of Intrahepatic ICCA in France (2017-2028)
Figure 33: Stage Specific Diagnosed Incident Cases of Extrahepatic ECCA in France (2017-2028)
Figure 34: Biomarker Specific Diagnosed Incident Cases of ICCA in France (2017-2028)
Figure 35: Biomarker Specific Diagnosed Incident Cases of ECCA in France (2017-2028)
Figure 36: Age Specific diagnosed Incident Cases of CCA in France (2017-2028)
Figure 37: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 39: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Figure 38: Gender Specific Incident Cases of CCA in Italy (2017-2028)
Figure 40: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Figure 41: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Figure 42: Biomarker Specific Diagnosed Incident Cases of ICCA in Italy (2017-2028)
Figure 43: Biomarker Specific Diagnosed Incident Cases of ERCCA in Italy (2017-2028)
Figure 44: Age Specific Diagnosed Incident Cases of ECCA in Italy (2017-2028)
Figure 45: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 47: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Figure 46: Gender Specific Incident Cases of CCA in Spain (2017-2028)
Figure 48: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Figure 49: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Figure 50: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 51: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 52: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Figure 53: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Figure 54: Gender Specific Incident Cases of CCA in the UK (2017-2028)
Figure 56: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Figure 57: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Figure 58: Biomarker Specific Diagnosed Incident Cases of ICCA in the UK (2017-2028)
Figure 59: Biomarker Specific Diagnosed Incident Cases of ECCA in the UK (2017-2028)
Figure 60: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Figure 61: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 63: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Figure 62: Gender Specific Incident Cases of CCA in Japan (2017-2028)
Figure 64: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Figure 65: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Figure 66: Biomarker Specific Diagnosed Incident Cases of ICCA in Japan (2017-2028)
Figure 67: Biomarker Specific Diagnosed Incident Cases of ECCA in Japan (2017-2028)
Figure 68: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Figure 69: Management algorithm for cholangiocarcinoma
Figure 70:  A suggested algorithm for the diagnosis and treatment of cholangiocarcinomas
Figure 71:  A suggested treatment algorithm for patients with iCCA
Figure 72:  Flowchart – Management and treatment of patients suspected of perihilar cholangiocarcinoma
Figure 73:  Algorithm for diagnosis and management of dCCA
Figure 74: Unmet Needs of Cholangiocarcinoma (CCA)
Figure 75: Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Figure 76: Market Size of Cholangiocarcinoma (CCA) in the US, USD Millions (2017-2028)
Figure 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Figure 78: Market Size of Cholangiocarcinoma (CCA) in Germany, USD Millions (2017-2028)
Figure 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Figure 80: Market Size of Cholangiocarcinoma (CCA) in France, USD Millions (2017-2028)
Figure 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Figure 82: Market Size of Cholangiocarcinoma (CCA) in Italy, USD Millions (2017-2028)
Figure 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Figure 84: Market Size of Cholangiocarcinoma (CCA) in Spain, USD Millions (2017-2028)
Figure 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Figure 86: Market Size of Cholangiocarcinoma (CCA) in UK, USD Millions (2017-2028)
Figure 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Figure 88: Market Size of Cholangiocarcinoma (CCA) in Japan, USD Millions (2017-2028)
Figure 89: Market Size of CCA by therapies in Japan in USD Million (2017-2028)
Figure 90: Market Drivers
Figure 91:Market Barriers

Table 1: TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 2: AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 3: MSKCC staging system for perihilar CCA
Table 4: TNM and AJCC/ UICC Staging Systems for Perihilar Cholangiocarcinoma
Table 5: TNM and AJCC/ UICC Staging Systems for distal extrahepatic Cholangiocarcinoma
Table 6: Risk Factors for Cholangiocarcinogenesis
Table 7: Host genetic polymorphism associated with cholangiocarcinoma
Table 8: Molecular aberrations in cholangiocarcinoma
Table 9: Differential diagnoses of the evaluation of CCA
Table 10: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 11: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the 7MM (2017-2028)
Table 12: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 13: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the US (2017-2028)
Table 14: Gender-Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 15: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the US (2017-2028)
Table 16: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the US (2017-2028)
Table 17: Biomarker Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 18: Age Specific Diagnosed Incident Cases of CCA in the US (2017-2028)
Table 19: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 20: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Germany (2017-2028)
Table 21: Gender-Specific Incident Cases of CCA in Germany (2017-2028)
Table 22: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Germany (2017-2028)
Table 23: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Germany (2017-2028)
Table 24: Biomarker Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 25: Age Specific Diagnosed Incident Cases of CCA in Germany (2017-2028)
Table 26: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 27: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in France (2017-2028)
Table 28: Gender-Specific Incident Cases of CCA in France (2017-2028)
Table 29: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in France (2017-2028)
Table 30: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in France (2017-2028)
Table 31: Biomarker Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 32: Age Specific Diagnosed Incident Cases of CCA in France (2017-2028)
Table 33: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 34: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Italy (2017-2028)
Table 35: Gender-Specific Incident Cases of CCA in Italy (2017-2028)
Table 36: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Italy (2017-2028)
Table 37: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Italy (2017-2028)
Table 38: Biomarker Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 39: Age Specific Diagnosed Incident Cases of CCA in Italy (2017-2028)
Table 40: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 41: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Spain (2017-2028)
Table 42: Gender-Specific diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 43: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Spain (2017-2028)
Table 44: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Spain (2017-2028)
Table 45: Biomarker Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 46: Age Specific Diagnosed Incident Cases of CCA in Spain (2017-2028)
Table 47: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 48: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in the UK (2017-2028)
Table 49: Gender-Specific Incident Cases of CCA in the UK (2017-2028)
Table 50: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in the UK (2017-2028)
Table 51: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in the UK (2017-2028)
Table 52: Biomarker Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 53: Age Specific Diagnosed Incident Cases of CCA in the UK (2017-2028)
Table 54: Total Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 55: Type-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) in Japan (2017-2028)
Table 56: Gender-Specific Incident Cases of CCA in Japan (2017-2028)
Table 57: Stage Specific Diagnosed Incident Cases of Intrahepatic CCA in Japan (2017-2028)
Table 58: Stage Specific Diagnosed Incident Cases of Extrahepatic CCA in Japan (2017-2028)
Table 59: Biomarker Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 60: Age Specific Diagnosed Incident Cases of CCA in Japan (2017-2028)
Table 61: Recommendations of British Society of Gastroenterology guidelines
Table 62: Recommendations of  Intrahepatic cholangiocarcinoma; Practice guidelines; Diagnosis and
Table 63: Key Cross: Emerging Therapies (III & II)
Table 64: Key Cross: Emerging Therapies (I)
Table 65: Key Cross: Emerging Therapies (I/II)
Table 66: AG-120, Clinical Trial Description, 2019
Table 67: INCB054828, Clinical Trial Description, 2019
Table 68: BGJ398, Clinical Trial Description, 2019
Table 69: Melphalan/HDS, Clinical Trial Description, 2019
Table 70: Derazantinib, Clinical Trial Description, 2019
Table 71: Regorafenib, Clinical Trial Description, 2019
Table 72: Larotrectinib, Clinical Trial Description, 2019
Table 73: Entrectinib, Clinical Trial Description, 2019
Table 74: Erdafitinib, Clinical Trial Description, 2019
Table 75:  Market Size of Cholangiocarcinoma (CCA) in 7MM in USD Million (2017-2028)
Table 76: The US Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 77: Market Size of CCA by therapies in the US in USD Million (2017-2028)
Table 78: Germany Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 79: Market Size of CCA by therapies in Germany in USD Million (2017-2028)
Table 80: France Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 81: Market Size of CCA by therapies in France in USD Million (2017-2028)
Table 82: Italy Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 83: Market Size of CCA by therapies in Italy in USD Million (2017-2028)
Table 84: Spain Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 85: Market Size of CCA by therapies in Spain in USD Million (2017-2028)
Table 86: UK Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 87: Market Size of CCA by therapies in the UK in USD Million (2017-2028)
Table 88: Japan Market Size of Cholangiocarcinoma (CCA) in USD Million (2017-2028)
Table 89:Market Size of CCA by therapies in Japan in USD Million (2017-2028)

Figure 1: Cholangiocarcinoma - Anatomical classification
Figure 2: Cholangiocarcinoma - Macroscopic types
Figure 3: Possible Risk Factor and Symptoms
Figure 4:  Cells of origin in Cholangiocarcinoma (CCA)
Figure 5:  Chronic Inflammation Cycle
Figure 6:  Function of wild-type and mutant IDH
Figure 7: